Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Ixico Plc (IXI) New Ord GBP0.01

Sell:89.00p Buy:92.00p 0 Change: 0.50p (0.56%)
Market closed Prices as at close on 1 March 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:89.00p
Buy:92.00p
Change: 0.50p (0.56%)
Market closed Prices as at close on 1 March 2021 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:89.00p
Buy:92.00p
Change: 0.50p (0.56%)
Market closed Prices as at close on 1 March 2021 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

IXICO plc is a brain health company. The Company's brain health focus includes Alzheimer's disease, Huntington's disease, Parkinson's disease, behavioral health and adolescent mental health. It is a provider of clinical trials services to pharmaceutical companies. Its products include Assessa, mehealth, MyBrainBook and TrialTracker. Assessa is a decision-support tool for healthcare professionals looking to diagnose dementia and detect the underlying causes. mehealth is an online software for clinicians at the point-of-care to support decision making and improve the monitoring and treatment of patients. MyBrainBook is a digital platform to improve the quality of life and service delivery for people living with dementia and their supporters. TrialTracker is a Web-based system that allows users to track their imaging-based research study or clinical trial in real time. It is also collaborating with partners to develop companion digital health products.

Contact details

Address:
4th Fl, Griffin Court, 15 Long Lane
LONDON
EC1A 9PN
United Kingdom
Telephone:
+44 (020) 37637499
Website:
https://ixico.com/

Important dates

Future events
There are no future events available.
Past events
AGM 21 January 2021 21/01/21
Final results 02 December 2020 02/12/20
Trading Announcement 19 October 2020 19/10/20
Trading Announcement 24 August 2020 24/08/20
Trading Announcement 24 June 2020 24/06/20
Interim results 20 May 2020 20/05/20
Trading Announcement 20 April 2020 20/04/20
Trading Announcement 14 April 2020 14/04/20

General stock information

EPIC:
IXI
ISIN:
GB00BFXR4C20
Market cap:
£42.80 million
Shares in issue:
47.29 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Giulio Cerroni
    Chief Executive Officer, Director
  • Grant Nash
    Chief Financial Officer, Executive Director
  • Michelle Lax
    Vice President - Clinical Operations
  • Conor Woolfson
    Group Financial Controller
  • Derek Hill
    Executive Director
  • Jane Whitrow
    Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.